Executive Summary

Canadian Dermatology Association writes FDA in support of monograph status for Givaudan-Roure's sunscreen ingredient Parsol 1789. R. W. Danby, MD, chair of CDA's Sunscreen Product Education Program, states in a June 22 letter that since the UVA ingredient's Canadian approval in 1989, "there have been a relatively small number of cases of allergic sensitization" to Parsol 1789-containing products. He cited "only two cases" of such adverse reactions. CDA's cutaneous adverse reaction program, he added, "confirms the lack of significant" adverse events